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Clinical improvement in a patient with
monostotic melorheostosis after treatment
with denosumab: a case report
Sarah Byberg1, Bo Abrahamsen2, Moustapha Kassem3, Stuart Ralston4 and Peter Schwarz1*
Abstract
Background: A 20-year-old Danish woman with melorheostosis in her right femoral shaft and disabling pain in the
affected area, whose symptoms did not in the long term respond to zoledronic acid, experienced continuous remission
of pain after treatment with denosumab. To the best of our knowledge, this is the first case report on denosumab
treatment for melorheostosis.
Case presentation: Radiologic findings and bone biopsy showed irregular cortical hyperostosis in the right femoral shaft
with increased tracer uptake on Tc99-bone scan.
The diagnosis of melorheostosis was made based on the radiological findings. There was a good initial response
to zoledronic acid administration, but after relapse of pain, the second and third administrations had a poor
effect. As a second line of treatment denosumab was administered at 8-week intervals, the frequency was based
on our patient’s symptoms and on biochemical markers of bone turnover.
Conclusion: This is the first report indicating that denosumab has a place in the treatment of melorheostosis when
the effect of bisphosphonate treatment is insufficient.
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Background
Melorheostosis is a rare, nonhereditary sclerosing bone
dysplasia first described in 1922 by Leri and Joanny [1].
The minimal prevalence has been estimated to be 0.9
per million [2]. Establishing the diagnosis melorheostosis
is challenging. It is primarily based on radiological find-
ings as defined by Freyschmidt [3] and on the exclusion
of other sclerosing bone diseases. It is a chronic progres-
sive disorder and affects females and males equally [3]
with no known curative treatment [4, 5]. Case reports
have documented pain relief by treatment with bispho-
sphonates [6–11].
This is the first report describing the treatment of
melorheostosis with denosumab. Denosumab was intro-
duced as a second line of treatment, after insufficient ef-
fect of zoledronic acid. Treatment with denosumab has
shown remarkable clinical effect.
Case presentation
A 20-year-old Danish woman was referred with constant
pain in the right proximal thigh that had progressed for
8 years. She had no other known medical conditions.
Menarche was at age 13. There was no family history of
sclerosing bone diseases. The limb pain was aggravated
at night and was moderately relieved during physical ac-
tivity and by cold baths. She was on daily analgesic
medication with nonsteroidal anti-inflammatory drugs,
paracetamol, and weak opioid agonists, and she was on
sick leave from her university studies at the time of re-
ferral due to her symptoms. She was using shoe inserts
because of leg length discrepancy.
At age 11 she had consulted a rheumatologist because
of hip joint pain. Guided by ultrasound a hip joint punc-
ture was performed due to fluid gathering; serology was
negative. After the puncture, the joint pain ceased.
Six months prior to referral to our clinic, she was
involved in a traffic accident and hit by a car from the
right at knee level. She was discharged from an emer-
gency room (ER) with no suspected fracture and a
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radiological examination was not performed. She re-
ported that there was significant worsening of the fem-
oral pain after the traffic accident.
Clinical findings
A clinical examination revealed no skin lesions, café au
lait spots, or redness; there was no increased temperature
or swelling in her right thigh. Leg length was unequal but
within normality.
Diagnostic assessment
She was instructed to fill out a diary with daily registra-
tion of pain on an analog scale from zero to 10, where
increasing values were equivalent to more intensive pain.
Orally administered analgesics were required when the
pain exceeded a score of 6 or more, and the score 10
was reserved for symptoms that kept our patient from
falling asleep and that did not respond adequately to or-
ally administered analgesics.
Magnetic resonance (MR) and positron emission
tomography-computed tomography (PET-CT) scans re-
vealed significant increased cortical thickness in the right
femoral diaphysis that partially obliterated the medullary
cavity (Fig. 1). The surface of the sclerotic bone was un-
even. A Tc99-bone scan showed a pathological increase
in uptake in most of the right femoral shaft (Fig. 2).
Biochemical bone markers were normal, including
normal alkaline phosphatase.
Screening for the GNAS1 activating mutation R201 was
negative in peripheral blood; as was mutation screening of
the SQSTM1 gene, which has been reported to be mutated
in Paget’s disease of bone.
A bone biopsy was performed and showed thickened
bone springs with preserved lamellar structure and
slightly accentuated cement lines. There was no fibrosis,
inflammation, or increased alcian positivity, which would
be suggestive of active osteomyelitis. There were no
signs of malignancy or neoplasia.
A gynecological examination prior to referral had found
a mild degree of polycystic ovaries (PCO) with normal an-
drogen status. There were no endocrinopathies.
Diagnostic reasoning and differential diagnosis
During the clinical investigation, four tentative diagnoses
were raised: atypical fibrous dysplasia, Paget’s disease of
bone, chronic non-infectious osteomyelitis, and melor-
heostosis. The young age of our patient, normal alkaline
phosphatase, and sparing of the metaphysis of the af-
fected bone made Paget’s disease of bone highly unlikely.
The cortical thickening is atypical for the diagnosis of fi-
brous dysplasia. The absence of café au lait spots, the nor-
mal age at menarche, the absence of other endocrine
disorders, and the negative GNAS1 mutation examination
weighed against a diagnosis of fibrous dysplasia. The long
Fig. 1 Computed tomography of right femoral shaft. Computed
tomography scan showing cortical thickening of the patien’s right
femoral shaft
Fig. 2 Bone scintigraphy whole body. Bone scintigraphy showing
the patient’s increased tracer uptake in the right femoral shaft
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bones are a common location for chronic non-infectious
osteomyelitis and this can present in childhood; however,
the radiological appearance and bone histology did not
provide support for this differential diagnosis. With special
emphasis on the uneven surface of the affected bone on
X-ray (Fig. 3), the diagnosis of melorheostosis, which was
fully compatible with the relatively unremarkable hist-
ology, was found to be the most plausible diagnosis. In
addition, the normal bone chemistry is in keeping with
melorheostosis [5] although in polyostotic cases alkaline
phosphatase can be increased [11].
Therapeutic intervention
The timeline for intervention and clinical outcome is
presented in Fig. 4. Initially, zoledronic acid 5 mg was
administered intravenously three times with 10-month
and 12-month intervals; our patient had pain relief after
the first administration, but a poor effect of the second
and third injection. Using an analog pain scale she re-
ported average pain of 9 prior to treatment, 6 after treat-
ment with zoledronic acid, and 4 from 2 to 10 months
after initiation of treatment with denosumab. Looking at
the usage of pain medication, it went from daily dosage
before treatment to 23% of days after treatment with
zoledronic acid, and to no orally administered analgesics
for 8 months following treatment with denosumab.
In October 2015, denosumab was chosen as the sec-
ond line of treatment based on the hypothesis that the
pain was caused by increased bone turnover. A dose of
60 mg was injected subcutaneously with some remission
of pain that lasted for 6 weeks. At the same time as the
pain relapsed, there was an increase in alkaline phos-
phatase, PINP, CTx, and osteocalcin in blood tests. Bio-
chemistry before and during treatment is listed in
Table 1. Based on these findings it was decided to
shorten the interval between administrations to further
strengthen control of a hypermetabolic state. The second
dose of 60 mg was given after 8 weeks and this interval
has been kept up to the present.
Biochemistry after treatment with both zoledronic acid
and denosumab showed suppression of bone-type basic
phosphatase, osteocalcin, collagen I, and procollagen I,
with a relative increase in parathyroid hormone, and
plasma ionized calcium within the normal range. The
injections with denosumab were well tolerated with no
adverse effects reported. During the whole treatment
period, the injections were administered from our
out-patient clinic without cancellations.
Follow-up and outcomes
After the first three doses given 8 weeks apart, there was
pain remission for 8 months; in this period our patient
did not take any orally administered analgesics. At the
latest follow-up in February 2018, she complained of a
slight increase in pain and occasional use of paracetamol
and nonsteroidal anti-inflammatory drugs.
The treatment with denosumab was well tolerated
with no side effects observed.
A Tc99-bone scan and computed tomography (CT)
scan were performed in February 2017 and in February
2018, 5 and 17 months after the first injection with
denosumab; the pathologically increased activity and
cortical thickening were stationary.
Discussion
Melorheostosis occurs sporadically [4]. The disease tends
to follow a sclerotomal distribution suggesting it originates
in a segmentary embryogenetic defect [12]. This case re-
port describes a case of monostotic sclerosing bone dis-
ease in an otherwise healthy young woman. The diagnosis
of melorheostosis is based on the radiological findings of
uneven hyperostosis of the proximal femur, also known as
a flowing candlewax configuration.
Tentative diagnoses have been excluded by: thorough
investigation of medical history; clinical, radiological,
and biochemical examinations; genetic testing; as well as
a biopsy of the affected bone. The bone biopsy was in-
formative only in the sense that it helped exclude active
inflammation, malignancy, and fibrous dysplasia. Melor-
heostosis has been associated with osteogenic sarcoma
[13, 14] and malignant fibrous histiocytoma [15]. Histo-
morphometric evaluation of a bone biopsy measuring 1
cm3 showed no sign of malignancy.
In this case report, pain is the only symptom. In other
studies of melorheostosis, pain has also been found to be
the most prevalent symptom [3]. Melorheostosis can be
monostotic or polyostotic and the lower limbs are most
often affected [3, 16], in some cases causing a difference in
limb length. Associated findings have been reported to be
Fig. 3 X-ray right femoral shaft. X-ray of the patient’s right femoral
shaft showing irregular hyperostosis
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soft tissue fibrosis in the affected area [17], deformity,
edema [11], and, rarely, vascular malformations [18].
These are reported in a minority of cases and in the
current case there were no associated findings.
It has been speculated whether loss-of-function muta-
tions in LEMD3 could be central to the pathophysiology
of melorheostosis; this mutation is usually not present in
cases of sporadic melorheostosis [19]. One research
group found that a number of genes coding for adhesion
proteins were downregulated in melorheostosis-related
skin lesions, with transforming growth factor-β (TGF-β)-
induced gene product (βig-h3) being the most signifi-
cantly affected [20].
In the medical literature, symptomatic relief has been
achieved with orthopedic surgery, analgesics, physical
therapy, and bisphosphonates [16]. This paper is the
first to document that treatment with denosumab has
a positive effect on disabling pain in a patient with
melorheostosis. The attenuating effect of denosumab
on biochemical markers of bone formation and on
clinical symptoms has been shown to last approxi-
mately 2 months. This may help to shed light on the
pathophysiology of a rare disease and points to a high
bone turnover. Denosumab was more effective for long
lasting pain relief than bisphosphonate in this case re-
port; therefore, one can speculate whether the disease
may be caused by local dysregulation in the RANK/
RANKL pathway.
A hypermetabolic state is also evident by the increased
tracer uptake in a bone scan; this is consistent with find-
ings in other reported cases of melorheostosis [5, 10].
Melorheostosis is a rare disease; it is heterogeneous in
its presentation, leaving some uncertainty in establishing
the diagnosis. However, among monostotic sclerosing
bone diseases, the irregular cortical hyperostosis is spe-
cific for this condition.
In conclusion, this is the first report indicating that
denosumab has a place in the treatment of melorheosto-
sis when the effect of bisphosphonate treatment is
insufficient.
Conclusion
The rationale for the conclusion
In this case of monostotic melorheostosis, there was a
recurrence of disabling pain after one injection with
Fig. 4 Timeline. Relevant data from this episode of care organized as a timeline. MRI magnetic resonance imaging, PET-CT positron emission
tomography-computed tomography
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zoledronic acid and lack of effect with repeated
administrations.
To halter the increased bone turnover a more power-
ful anti-reabsorptive agent was chosen with the RANKL
inhibitor denosumab. In this case, there was pain relief
for 6 weeks after the first administration. At this time
the pain intensity increased again, with a slight increase
in bone markers. One could speculate if this was indi-
cative of an underlying state of increased consumption
of osteoprotegerin. It was decided to shorten the inter-
val between administrations to 8 weeks resulting in
continuous pain remission for the following 8 months.
The stationary findings on bone scintigraphy after 1.5
years of treatment might be explained by the size of the
affected area, and thus we expect decreased activity in
future scans.
The primary “take-away” lesson from this case report
This is the first report indicating that denosumab has a
place in the treatment of melorheostosis when the effect
of bisphosphonate treatment is insufficient.
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